Age-related Macular Degeneration // Clinical Trials // Michael Altaweel // Neovascular AMD // Past // Sep 28 2020

A 64-Week, Two-Arm, Randomized, Double-Masked, Multi-Center, Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-To-Control Regimen in Patients with Neovascular Age-Related Macular Degeneration (TALON)

Sponsor: Novartis Pharmaceuticals